Cite
HARVARD Citation
Harvey, R. et al. (2020). Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of oncology pharmacy practice. pp. 1461-1474. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Harvey, R. et al. (2020). Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of oncology pharmacy practice. pp. 1461-1474. [Online].